Drug details

Tasigna Capsules (nilotinib capsules)

type of Antineoplastic Tyrosine Kinase Inhibitors

Tasigna (nilotinib) is a kinase inhibitor that interferes with a protein that signals cancer cells to multiply used to treat adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase of the disease; it is also used to treat both chronic and accelerated Philadelphia chromosome positive myeloid leukemia in adults that are resistant or intolerant to prior therapy, including imatinib. Tasigna is available in generic form.

This drug may have the following side effects:

• nausea,
• headache,
• diarrhea,
• itching,
• constipation,
• skin rash,
• tiredness,
• back pain,
• fatigue,
• temporary hair loss, or
• joint or muscle aches or pain,
• cold symptoms (stuffy nose, sneezing, cough, or sore throat).

The following drugs are related to Tasigna Capsules, either as a replacement or used together:

• Campath (alemtuzumab)
• Trisenox (arsenic trioxide injection)
• Arzerra (ofatumumab injection)
• Elspar (asparaginase)
• Erwinaze (asparaginase erwinia chrysanthemi)
• Asparlas (calaspargase pegol-mknl injection)
• Bendeka (bendamustine hydrochloride injection)
• Blincyto (blinatumomab for injection)
• Bosulif (bosutinib tablets)
• Busulfex (busulfan)
• Cerubidine (daunorubicin)
• Leustatin (cladribine injection for intravenous infusion only)
• Cytoxan (cyclophosphamide)
• Gleevec (imatinib mesylate)
• Tibsovo (ivosidenib tablets)
• Synribo (omacetaxine mepesuccinate)
• Vincristine Sulfate Injection (vincristine sulfate)